TRUMP CARD’ SCHEME BOTCHES $150-M CUT IN DRUG PRICES
US President Donald Trump threw away a deal that would have reduced $150-million from drug prices for seniors all because the White House chief of staff Mark Meadows demanded that pharmaceutical firms pay for the $100 Trump cards to be mailed to seniors before the Nov. 3 election.
Bob Brigham wrote for Raw Story on September 19, 2020 that the scheme was akin to Trump’s “trying to buy votes like a mob boss.”
“After months of heated accusations and painstaking negotiations, the White House and the pharmaceutical industry neared agreement late last month on a plan to make good on President Trump’s longstanding promise to lower drug prices. The drug companies would spend $150 billion to address out-of-pocket consumer costs and would even pick up the bulk of the co-payments that older Americans shoulder in Medicare’s prescription drug program,” Maggie Haberman wrote for the New York Times.
“Then the agreement collapsed. The breaking point, according to four people familiar with the discussions: Mark Meadows, Mr. Trump’s chief of staff, insisted the drug makers pay for $100 cash cards that would be mailed to seniors before November — ‘Trump Cards,’ some in the industry called them,” the newspaper reported. “Some of the drugmakers bridled at being party to what they feared would be seen as an 11th-hour political boost for Mr. Trump, the people familiar with the matter said,” New York Times added. The White House was naturally blasted for the collapse of negotiations, which showed that pharmaceutical firms are capable of illustrating moral certainty and eschewing corruption, Brigham concluded.
The Financial District would like to learn more from its audience. Can you please give us feedback on this article you just read. Click Here to participate in our online survey.